Abstract
Overview
Introduction
With the seven triptan brands continuing to dominate acute migraine treatment
and Ortho-McNeil' s Topamax (topiramate) driving sales in the prophylactic
market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to
$3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006,
Whilst in the 5EU, France is the largest market for migraine-specific drug
sales.
Scope
- This report focuses on acute and prophylactic drugs used to treat
migraine, with indication- and country-specific sales and volume forecasts to
2016
- Assessment of current and future opportunities and threats in the migraine
market across the 7MMs and in individual regions
- Analysis and quantification of future market events expected to impact
anti-migraine drug revenues over the next decade
- Case study analysis of successful lifecycle management strategies and
scenario forecasts provide further market insight and key recommendations
Highlights
GSK has executed a number of well-timed lifecycle management strategies that
have ensured Imitrex' s market leadership. However, Imitrex' s impending patent
expiry will result in generic sumatriptan flooding the US market in late 2008,
and crucial delays to Trexima' s launch will signal the end of GSK' s dominance
of the migraine market.
There remains substantial opportunity in the migraine prophylaxis market. In
spite of US Topamax patent expiry in 2008, the large number of untreated
patients and poor tolerability profiles of existing treatments means the
prophylactic market will remain highly attractive over the forecast period.
Menstrual migraine (MM) represents an unknown, yet potentially rewarding
market opportunity. Endo and Vernalis' s Frova (frovatriptan) awaits the FDA' s
decision on its application for the short-term prevention of MM. This outcome
will be crucial to the drug' s future and will also influence other triptan
manufacturers' decision to pursue MM.
Reasons to Purchase
- Quantify the future size of the migraine market, in terms of prescription
volume and value, in each of the seven major markets
- Assess the impact of future events such as patent expiries, indication
expansions, and new product launches on the sales of key marketed brands
- Identify key lifecycle management strategies and market opportunities that
can ensure growth in the competitive anti-migraine pharmaceutical arena
View Cart
